- Home
- ARMP vs CTSO Comparison
ARMP vs CTSO Comparison
Compare ARMP & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- CTSO
- Stock Information
- Founded
- ARMP N/A
- CTSO 1997
- Country
- ARMP United States
- CTSO United States
- Employees
- ARMP N/A
- CTSO N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- CTSO Medical/Dental Instruments
- Sector
- ARMP Health Care
- CTSO Health Care
- Exchange
- ARMP Nasdaq
- CTSO Nasdaq
- Market Cap
- ARMP 52.1M
- CTSO 61.3M
- IPO Year
- ARMP N/A
- CTSO N/A
- Fundamental
- Price
- ARMP $1.23
- CTSO $1.03
- Analyst Decision
- ARMP Strong Buy
- CTSO Strong Buy
- Analyst Count
- ARMP 1
- CTSO 3
- Target Price
- ARMP $7.00
- CTSO $4.67
- AVG Volume (30 Days)
- ARMP 30.3K
- CTSO 74.6K
- Earning Date
- ARMP 05-06-2025
- CTSO 05-08-2025
- Dividend Yield
- ARMP N/A
- CTSO N/A
- EPS Growth
- ARMP N/A
- CTSO N/A
- EPS
- ARMP N/A
- CTSO N/A
- Revenue
- ARMP $5,174,000.00
- CTSO $35,594,520.00
- Revenue This Year
- ARMP $8.43
- CTSO $18.72
- Revenue Next Year
- ARMP N/A
- CTSO $19.75
- P/E Ratio
- ARMP N/A
- CTSO N/A
- Revenue Growth
- ARMP 14.24
- CTSO 14.51
- 52 Week Low
- ARMP $0.90
- CTSO $0.70
- 52 Week High
- ARMP $3.45
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- ARMP 39.22
- CTSO 53.19
- Support Level
- ARMP $1.11
- CTSO $0.93
- Resistance Level
- ARMP $1.30
- CTSO $1.07
- Average True Range (ATR)
- ARMP 0.14
- CTSO 0.06
- MACD
- ARMP 0.01
- CTSO 0.01
- Stochastic Oscillator
- ARMP 42.86
- CTSO 71.43
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.